Last reviewed · How we verify
NCT03439878
Effect of Galactose Ingestion on Postprandial Lipemia
NA trial testing Galactose in Cardiovascular Risk Factor in 10 participants. Completed in 1 May 2018.
1 May 2018
Quick facts
| Lead sponsor | University of Bath |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 10 |
| Start date | 1 February 2018 |
| Primary completion | 1 May 2018 |
| Estimated completion | 1 May 2018 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
Conditions studied
- Cardiovascular Risk Factor — all drugs for Cardiovascular Risk Factor →
- Lipemia — all drugs for Lipemia →
Sponsor
University of Bath
Who can join
Adults 18 to 35, male only, with Cardiovascular Risk Factor or Lipemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to assess the postprandial triglyceride response to the ingestion of a high-fat meal with co-ingestion of either galactose, or glucose.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Galactose Ingested with a High-Fat Beverage Increases Postprandial Lipemia Compared with Glucose but Not Fructose Ingestion in Healthy Men.
Watkins J, Simpson A, Betts JA, Thompson D, et al · · 2020 · cited 11× · PMID 32297937 · DOI 10.1093/jn/nxaa105
Verify or expand the search:
- PubMed search for NCT03439878
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Galactose
Trials testing the same drug.
- NCT05986500 — The GALAXY-1 Project · NA · unknown
Other recruiting trials for Cardiovascular Risk Factor
Currently open trials in the same condition.
- NCT07268781 — Impact of Golden Rice-Piper Crocatum Cookies on Lipid Control in Diabetes Mellitus Patients · NA · active not recruiting
- NCT06225544 — Lumasiran in Hyperoxalaemic Patients on Haemodialysis · Phase 2 · recruiting
- NCT06372054 — TORNADO-Omics Techniques and Neural Networks for the Development of Predictive Risk Models · recruiting
- NCT05887622 — The Potassium Supplementation Study · NA · recruiting
- NCT04962061 — A Combined Multidomain Intervention to Prevent Cognitive Decline Associated With Cardiovascular Risk Factors. · NA · recruiting
Other University of Bath trials
Trials by the same sponsor.
- NCT07360249 — Glucose-fructose Ratio Pilot · NA · recruiting
- NCT06967077 — Exploring the Feasibility and Acceptability of Virtual Reality Exercise for Pain Management, Fear of Movement, Mobility, · NA · not yet recruiting
- NCT07472244 — Does the Development of the Repeated Bout Effect Depend on Oxidative Stress and Inflammation? · NA · recruiting
- NCT07099911 — Neuromuscular Electrical Stimulation and Glucose Control in Spinal Cord Injury · NA · recruiting
- NCT07027553 — Remote Exercise to Improve Physical Activity Levels and Markers of Heart Health in Cystic Fibrosis (RHH-CF) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03439878 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Bath
- Last refreshed: 24 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03439878.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing